Driven by discoveries of the molecular causes of cancer and revolutionary therapies, such as immunotherapy, the transformation of many cancer types … | BY DR. OSCAR SEGURADO about Why we need a Cancer Care Act
personalized and precision medicine: clinical development of drugs, devices and biomarkers - medical affairs - pharmacovigilance - health economics - reimbursement
key therapeutic areas
oncology - immuno-oncology - hemato-oncology - hematology - rare diseases - genomics - gene therapy - autoimmunity - immunology - immunotherapy - inflammatory diseases - neurology - rheumatology - cardiovascular - metabolic diseases - integrative medicine
key functional expertise
study planning, design, execution, interpretation, publication - discovery - translational research - Phase I-IV - investigator-initiated studies - outcomes research - companion diagnostics - health economics and reimbursement - interactions with internal and external stakeholders
MEDICAFFAIRS supports pharmaceutical, medical devices and diagnostic companies in ‘Translating Clinical Research into Medical Practice’.
MEDICAFFAIRS provides medical affairs expertise for translational medicine, clinical trial design and execution, regulatory approvals, internal and external liaisons, reimbursement and health economics.
Our key principles: We value trust and close cooperation with our clients
cooperation is vital,
The accelerating pace of scientific breakthroughs in medical science, bioinformatics, and digital healthcare captivates the world’s imagination. … | BY DR. OSCAR SEGURADO about Beyond the moonshot: Achieving universal cancer care
On Nov. 18, the Food and Drug Administration (FDA) announced that an oversight policy regulating laboratory developed tests (LDTs) will be put on … | BY DR. OSCAR SEGURADO about FDA hold on guidance for laboratory developed tests is a wise action